Abstract: Methods for treating and/or delaying onset of dysplastic lesions in the bronchial airway of an individual comprise delivering to the respiratory track of the individual an inhalable dry powder composition including an effective amount of myo-inositol.

Abstract: Methods for treating and/or delaying onset of dysplastic lesions in the bronchial airway of an individual comprise delivering to the respiratory track of the individual an inhalable dry powder composition including an effective amount of myo-inositol.

Abstract: In one embodiment, a human-powered dry powder inhaler comprises a human-powered compressible component operable to discharge an air pulse at an outlet at a pressure of about 1-40 psi; an inflatable reservoir operable to receive an air pulse discharged from the human-powered compressible component to provide an aerosol of a dry powder pharmaceutical formulation in the reservoir, the reservoir including an outlet valve; and a receiving mask in communication with the outlet valve and operable to receive an aerosol of dry powder from the reservoir and to deliver the aerosol to at least a mouth or nose of a patient. In another embodiment, the inhaler comprises a human-powered compressible component operable to discharge an air pulse at an outlet of a polymeric pressure release valve at a pressure of about 1-40 psi; and a receiving mask in communication with the outlet of the compressible component and operable to deliver an aerosol of dry powder to at least a mouth or nose of a patient.